<p>当你购买一家公司的股票时，总是存在价格跌至零的风险。另一方面，如果你找到一家高质量的企业进行投资（以合适的价格），你可以将资金翻倍！以 <strong>微创医疗</strong>（HKG:853）为例。其股价在过去十二个月中已经上涨了令人印象深刻的 149%。在过去一个季度，股价也上涨了 70%。该公司最近公布了财务业绩；你可以通过阅读我们的公司报告来了解最新数据。不幸的是，从长期来看，回报并不理想，股票在过去三年中下跌了 1.5%。</p>
<p>由于长期表现良好，但最近回调了 3.7%，我们来检查一下基本面是否与股价相符。</p>
<p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整名单是免费的。</p>
<p>由于微创医疗在过去十二个月中出现了亏损，我们认为市场可能更关注收入和收入增长，至少目前是这样。无盈利公司的股东通常希望看到强劲的收入增长。一些公司愿意推迟盈利以更快地增长收入，但在这种情况下，人们希望看到良好的收入增长来弥补缺乏盈利。</p>
<p>在过去一年中，微创医疗的收入缩减了 0.7%。我们对股价在过去一年中上涨 149% 感到有些惊讶。这是一个很好的例子，说明买家如何在基本指标显示出增长之前就推高价格。无论如何，收入下降很可能已经被市场定价。</p>
<p>下图显示了收益和收入随时间的变化（如果你点击图像，可以看到更详细的信息）。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26049405-earnings-and-revenue-growth-1-dark-2/1758320197908?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26049405-earnings-and-revenue-growth-1-dark-2/1758320197908"/></p>
<p>SEHK:853 收益和收入增长 2025 年 9 月 19 日</p>
<p>看到在过去三个月中有一些显著的内部人士购买是件好事。这是一个积极的信号。不过，我们认为收益和收入增长趋势是更重要的考虑因素。因此，我们建议查看这份 <strong>免费的</strong> 报告，显示共识预测。</p>
<h2>不同的视角</h2>
<p>我们很高兴地报告，微创医疗的股东在一年内获得了 149% 的总股东回报。这确实超过了过去五年每年约 9% 的损失。这让我们有些警惕，但该业务可能已经扭转了局面。虽然考虑市场条件对股价的不同影响是非常值得的，但还有其他因素更为重要。例如风险——微创医疗有 <strong>1 个警告信号</strong> 我们认为你应该注意。</p>
<p>微创医疗并不是唯一一家内部人士在购买的股票。因此，看看这份 <strong>免费的</strong> 小型公司名单，这些公司在吸引人的估值下被内部人士购买。</p>
<p><em>请注意，本文中引用的市场回报反映了目前在香港交易所交易的股票的市场加权平均回报。</em></p>

微创医疗

<p>微创医疗（HKG:853）的股东在过去一年中见证了股价的显著增长，达到 149%，尽管最近出现了 9.7 亿港元的下降。该股票在上个季度上涨了 70%，尽管过去一年收入下降了 0.7%。公司面临挑战，包括三年内下降了 1.5%，并且最近出现了亏损。过去三个月的内部人士买入是一个积极的信号，但由于潜在风险，建议保持谨慎。总体而言，该股票的表现引发了对其基本面的质疑</p>

<p>When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find a high quality business to buy (at the right price) you can more than double your money! Take, for example <strong>MicroPort Scientific Corporation</strong> (HKG:853). Its share price is already up an impressive 149% in the last twelve months. It's also good to see the share price up 70% over the last quarter. The company reported its financial results recently; you can catch up on the latest numbers by reading our company report. Unfortunately the longer term returns are not so good, with the stock falling 1.5% in the last three years.</p>
<div class="lb-trans"><p>当你购买一家公司的股票时，总是存在价格跌至零的风险。另一方面，如果你找到一家高质量的企业进行投资（以合适的价格），你可以将资金翻倍！以 <strong>微创医疗</strong>（HKG:853）为例。其股价在过去十二个月中已经上涨了令人印象深刻的 149%。在过去一个季度，股价也上涨了 70%。该公司最近公布了财务业绩；你可以通过阅读我们的公司报告来了解最新数据。不幸的是，从长期来看，回报并不理想，股票在过去三年中下跌了 1.5%。</p>
</div><p>Since the long term performance has been good but there's been a recent pullback of 3.7%, let's check if the fundamentals match the share price.</p>
<div class="lb-trans"><p>由于长期表现良好，但最近回调了 3.7%，我们来检查一下基本面是否与股价相符。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整名单是免费的。</p>
</div><p>Because MicroPort Scientific made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.</p>
<div class="lb-trans"><p>由于微创医疗在过去十二个月中出现了亏损，我们认为市场可能更关注收入和收入增长，至少目前是这样。无盈利公司的股东通常希望看到强劲的收入增长。一些公司愿意推迟盈利以更快地增长收入，但在这种情况下，人们希望看到良好的收入增长来弥补缺乏盈利。</p>
</div><p>In the last year MicroPort Scientific saw its revenue shrink by 0.7%. We're a little surprised to see the share price pop 149% in the last year. This is a good example of how buyers can push up prices even before the fundamental metrics show much growth. It's quite likely the revenue fall was already priced in, anyway.</p>
<div class="lb-trans"><p>在过去一年中，微创医疗的收入缩减了 0.7%。我们对股价在过去一年中上涨 149% 感到有些惊讶。这是一个很好的例子，说明买家如何在基本指标显示出增长之前就推高价格。无论如何，收入下降很可能已经被市场定价。</p>
</div><p>The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).</p>
<div class="lb-trans"><p>下图显示了收益和收入随时间的变化（如果你点击图像，可以看到更详细的信息）。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26049405-earnings-and-revenue-growth-1-dark-2/1758320197908" alt="" original-src="https://images.simplywall.st/asset/chart/26049405-earnings-and-revenue-growth-1-dark-2/1758320197908"/></p>
<p>SEHK:853 Earnings and Revenue Growth September 19th 2025</p>
<div class="lb-trans"><p>SEHK:853 收益和收入增长 2025 年 9 月 19 日</p>
</div><p>It's good to see that there was some significant insider buying in the last three months. That's a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. So we recommend checking out this <strong>free</strong> report showing consensus forecasts</p>
<div class="lb-trans"><p>看到在过去三个月中有一些显著的内部人士购买是件好事。这是一个积极的信号。不过，我们认为收益和收入增长趋势是更重要的考虑因素。因此，我们建议查看这份 <strong>免费的</strong> 报告，显示共识预测。</p>
</div><h2>A Different Perspective</h2>
<div class="lb-trans"><h2>不同的视角</h2>
</div><p>We're pleased to report that MicroPort Scientific shareholders have received a total shareholder return of 149% over one year. That certainly beats the loss of about 9% per year over the last half decade. This makes us a little wary, but the business might have turned around its fortunes. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - MicroPort Scientific has <strong>1 warning sign</strong> we think you should be aware of.</p>
<div class="lb-trans"><p>我们很高兴地报告，微创医疗的股东在一年内获得了 149% 的总股东回报。这确实超过了过去五年每年约 9% 的损失。这让我们有些警惕，但该业务可能已经扭转了局面。虽然考虑市场条件对股价的不同影响是非常值得的，但还有其他因素更为重要。例如风险——微创医疗有 <strong>1 个警告信号</strong> 我们认为你应该注意。</p>
</div><p>MicroPort Scientific is not the only stock insiders are buying. So take a peek at this <strong>free</strong> list of small cap companies at attractive valuations which insiders have been buying.</p>
<div class="lb-trans"><p>微创医疗并不是唯一一家内部人士在购买的股票。因此，看看这份 <strong>免费的</strong> 小型公司名单，这些公司在吸引人的估值下被内部人士购买。</p>
</div><p><em>Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.</em></p>
<div class="lb-trans"><p><em>请注意，本文中引用的市场回报反映了目前在香港交易所交易的股票的市场加权平均回报。</em></p>
</div>

尽管微创医疗（HKG:853）的市值在过去一周内缩水了 9.7 亿港元，但其股东在一年内的收益仍然上涨了 149%